Cory Freedland

Prior to joining Novo Ventures, Cory was a Vice President in Morgan Stanley’s healthcare investment banking practice where he executed strategic and financing transactions for biopharmaceutical and medical technology companies. Before transitioning to investment banking, Cory spent five years with Roche Palo Alto focused on novel target discovery for central nervous system diseases including schizophrenia and Alzheimer’s disease. Cory received a PhD in Pharmacology from Wake Forest University School of Medicine, an MBA from the Kellogg School of Management and a BA from Connecticut College